Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals announced the U.S. commercial availability of NEREUS (tradipitant) for the prevention of motion sickness, marking the first new prescription treatment for this condition in over 40 years. The drug is available via a direct-to-consumer platform and retail pharmacies, with a cash-pay price of $85 per dose compared to a standard list price of $255.
Key figures
- Drug Name
- NEREUS (tradipitant)
- Phase Of Trial
- Phase 3
- Cash pay price
- $85 per dose
- Affected population
- 65 to 78 million Americans
- Standard list price
- $255 per dose
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.